Multiple Sclerosis Fellowship
- Program Director
- Multiple Sclerosis Fellowship Program
The Comprehensive Multiple Sclerosis Center utilizes an integrated approach to diagnosis and treatment of Multiple Sclerosis and other neuroimmunological disorders.
It serves as a tertiary referral and teaching center and is allied with a multispecialty team of practitioners. It has special programs for clinically isolated syndromes, transverse myelitis, and spasticity management. Fellows have an opportunity to participate in ongoing clinical and ex vivo research into the immunology of neurological disorders, new treatment and diagnostic approaches, novel imaging modalities, and outcome and genetic studies in MS.
The Laboratory of Neuroimmunology offers qualified candidates further opportunities in basic and translational research in Multiple Sclerosis.
- Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary
- Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
- Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
- Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: A plain language summary
- T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy